Phase 1 Study of the Anti-Ron Receptor Monoclonal Antibody IMC-RON8 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available.
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2017
At a glance
- Drugs Narnatumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 04 Feb 2017 Results published in the Investigational New Drugs
- 29 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.